OBIO
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a significant premium to book value; valuation is based on future pipeline rather than current fundamentals.
- Significant upside to analyst target price
- High Price/Book (4.87)
- High Price/Sales (7.99)
- No Graham Number available due to lack of earnings
Growth metrics are extreme, suggesting a transition from R&D to commercialization or milestone payments.
- 12,120% YoY revenue growth
- Recent EPS surprise of +168.7%
- Strong buy recommendation from 7 analysts
- Sustainability of growth from a near-zero base
Long-term historical performance has been poor, though short-term momentum is improving.
- 1-year price recovery of +62.1%
- 3-year change of -79.2%
- 5-year change of -56.0%
Deterministic health is very weak (F-Score), though the balance sheet provides a temporary liquidity cushion.
- Low Debt/Equity (0.25)
- High Current Ratio (6.45)
- Piotroski F-Score of 1/9
- Negative ROE (-109.41%)
- Negative ROA (-33.90%)
Non-dividend paying growth company.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OBIO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OBIO
Orchestra BioMed Holdings, Inc.
Primary
|
-56.0% | -79.2% | +62.1% | +24.9% | +0.4% | +7.0% |
|
EOLS
Evolus, Inc.
Peer
|
-69.9% | -50.5% | -56.3% | -34.1% | -23.6% | -5.1% |
|
MASS
908 Devices Inc.
Peer
|
-85.9% | -13.6% | +62.9% | -8.5% | +18.6% | +5.1% |
|
CLPT
ClearPoint Neuro, Inc.
Peer
|
-59.8% | -1.5% | -17.2% | -65.6% | -21.4% | -0.3% |
|
CARL
Carlsmed, Inc.
Peer
|
-32.8% | -32.8% | -32.8% | -28.3% | -18.4% | +7.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OBIO
Orchestra BioMed Holdings, Inc.
|
NEUTRAL | $267.44M | - | -109.4% | -157.4% | $4.57 | |
|
EOLS
Evolus, Inc.
|
NEUTRAL | $266.1M | - | -% | -17.4% | $4.09 | Compare |
|
MASS
908 Devices Inc.
|
BEARISH | $269.14M | - | -25.8% | 34.7% | $7.2 | Compare |
|
CLPT
ClearPoint Neuro, Inc.
|
BEARISH | $269.82M | - | -95.6% | -69.1% | $9.07 | Compare |
|
CARL
Carlsmed, Inc.
|
NEUTRAL | $260.37M | - | -47.6% | -58.7% | $9.74 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | HOCHMAN DAVID P | Chief Executive Officer | Purchase | 10,000 | $42,900 |
| 2026-02-12 | SHERMAN DARREN | President | Stock Award | 397,000 | - |
| 2026-02-12 | TAYLOR ANDREW LAWRENCE | Chief Financial Officer | Stock Award | 181,000 | - |
| 2026-02-12 | HOCHMAN DAVID P | Chief Executive Officer | Stock Award | 504,000 | - |
| 2025-11-14 | HOCHMAN DAVID P | Chief Executive Officer | Purchase | 5,000 | $20,350 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning OBIO from our newsroom.